12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MGN1601: Updated Phase I/II data

Updated data from 10 evaluable patients who completed 12 weeks of treatment in the open-label, German Phase I/II ASET trial showed that MGN1601 led to median overall survival (OS) of >16 months and produced 7 cases of stable disease. The most common adverse events were...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >